INmune Bio
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $50 |
Gross Profit | -56 | -28 | 50 | |
EBITDA | -5,418 | -6,444 | -8,057 | -9,905 |
EBIT | -5,474 | -6,472 | ||
Net Income | -5,264 | -6,472 | -24,458 | -9,739 |
Net Change In Cash | 0 | 0 | 0 | 50 |
Free Cash Flow | -3,660 | -5,632 | -8,080 | -6,824 |
Cash | 24,751 | 27,734 | 33,374 | 19,337 |
Basic Shares | 26,585 | 26,585 | 23,298 | 22,496 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $50 | $14 | $155 | $374 |
Gross Profit | 50 | 14 | 155 | 374 |
EBITDA | -30,785 | -42,082 | -29,741 | -27,299 |
EBIT | -30,869 | -42,635 | -59,482 | -25,951 |
Net Income | -45,933 | -42,082 | -30,008 | -28,647 |
Net Change In Cash | 50 | 14 | 155 | 374 |
Cost of Revenue | -21,957 | |||
Free Cash Flow | -23,624 | -33,361 | -11,980 | -22,686 |
Cash | 24,751 | 20,922 | 35,848 | 52,153 |
Basic Shares | 26,585 | 19,944 | 17,981 | 17,927 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.19 |
2025-12-31 | -$0.18 |
2025-09-30 | -$0.24 |
2025-06-30 | -$0.34 |
